PPA
TERN

Parametric Portfolio Associates’s Terns Pharmaceuticals TERN Stock Holding History

Parametric Portfolio Associates’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$62K Buy
20,784
+8,467
+69% +$36.1K ﹤0.01% 3614
2021
Q4 		$87K Buy
+12,317
New +$103K ﹤0.01% 3568

Other funds holding TERN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Parametric Portfolio Associates's TERN Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Terns Pharmaceuticals (TERN) stake by 69% in Q1 2022, buying an estimated $36.1K and bringing the position to 20,784 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Parametric Portfolio Associates first reported a position in TERN in Q4 2021 and has held it in 2 quarters since. The position peaked at $87K in Q4 2021. 44 funds tracked by Wall St. Rank hold TERN as of Q1 2022.

  • Parametric Portfolio Associates held 20,784 shares of Terns Pharmaceuticals worth $62K as of Q1 2022.
  • Parametric Portfolio Associates bought 8,467 Terns Pharmaceuticals shares in Q1 2022, an estimated $36.1K.
  • Terns Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3614 holding.
  • Parametric Portfolio Associates first reported a position in Terns Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Parametric Portfolio Associates's Terns Pharmaceuticals position peaked at $87K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.